Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Marika, Cinausero"'
Autor:
Lucia Fratino, Jerry Polesel, Emilio Francesco Giunta, Marco Maruzzo, Sebastiano Buti, Mona Ali Hassan, Umberto Basso, Sara Elena Rebuzzi, Ugo De Giorgi, Marika Cinausero, Helga Lipari, Teresa Gamba, Davide Bimbatti, Arianna Dri, Paola Ermacora, Francesca Vignani, Giuseppe Fornarini, Pasquale Rescigno, Giuseppe Luigi Banna
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Instrumental activities of daily living (IADL) are significant health indicators closely related to executive functions and able to detect mild cognitive impairment. A decline in IADL usually precedes ADL limitation, including taking medicat
Externí odkaz:
https://doaj.org/article/6a0ab27419da4917ac402a86c95934eb
Autor:
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Publikováno v:
Therapeutic Advances in Urology, Vol 16 (2024)
Background: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. Objectives: The primary objective was to assess the effectiveness of the lenvatinib plus e
Externí odkaz:
https://doaj.org/article/8b27ee40f25b4013b6d8493402a39273
Autor:
Giuseppe Luigi Banna, Umberto Basso, Emilio Francesco Giunta, Lucia Fratino, Sara Elena Rebuzzi, Sebastiano Buti, Marco Maruzzo, Ugo De Giorgi, Veronica Murianni, Marika Cinausero, Helga Lipari, Teresa Gamba, Orazio Caffo, Davide Bimbatti, Arianna Dri, Alessandra Mosca, Paola Ermacora, Francesca Vignani, Aichi Msaki, Barbara Bonifacio, Valentina Lombardo, Vincenza Conteduca, Giuseppe Fornarini, Pasquale Rescigno
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7745-7753 (2022)
Introduction: Androgen receptor pathway inhibitors (ARPIs) have been increasingly offered to older patients with prostate cancer (PC). However, prognostic factors relevant to their outcome with ARPIs are still little investigated. Methods and Materia
Externí odkaz:
https://doaj.org/article/9af65c31e22e4c4daa86343bb2d1ded2
Autor:
Arianna Dri, Silvio Ken Garattini, Marika Cinausero, Marianna Macerelli, Martina Fanelli, Fabio Puglisi, Gianpiero Fasola, Paola Ermacora
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 6776-6786 (2022)
The advent of immune checkpoint inhibitors in combination with multitarget tyrosine kinase inhibitors has become a standard first-line treatment for metastatic renal cell cancer. Along with survival improvement, new toxicities have emerged. Such adve
Externí odkaz:
https://doaj.org/article/852616dc40844039a3f0c09a7c5756b4
Autor:
Debora Basile, Lorenzo Gerratana, Carla Corvaja, Giacomo Pelizzari, Giorgia Franceschin, Elisa Bertoli, Lorenza Palmero, Diego Zara, Martina Alberti, Silvia Buriolla, Lucia Da Ros, Marta Bonotto, Mauro Mansutti, Simon Spazzapan, Marika Cinausero, Alessandro Marco Minisini, Gianpiero Fasola, Fabio Puglisi
Publikováno v:
Breast, Vol 57, Iss , Pp 104-112 (2021)
Background: Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents the standard treatment for luminal-metastatic breast cancer (MBC). However, prospective head-to-head comparisons are still lacking for 1st line (L) o
Externí odkaz:
https://doaj.org/article/ffca05a7c1374d128a76cb6fc5f88ba4
Autor:
Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino, Anna Squadrilli, Gianpiero Fasola, Massimo Negrini, Marcello Tiseo, Manuela Ferracin, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors represent novel therapeutic options for advanced non-small cell lung cancer (NSCLC). However, approximately 50% of patients do not benefit from therapy and experience rapid
Externí odkaz:
https://doaj.org/article/bbe74f39c6134ab4a55c01b9a32b30e3
Autor:
Emanuela Dell'Aquila, Chiara Carlomagno, Carmine Pinto, Giorgio Reggiardo, Domenico Corsi, Alfredo Colombo, Gerardo Rosati, Giuseppe Cicero, Domenico Bilancia, Antonio Avallone, Giuseppe Aprile, Stefania Rapisardi, Marika Cinausero, Silvia Brugnatelli
Publikováno v:
Journal of Geriatric Oncology. 13:302-307
Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with me
Autor:
Pasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, Veronica Murianni, Marika Cinausero, Helga Lipari, Lucia Fratino, Teresa Gamba, Ugo De Giorgi, Orazio Caffo, Davide Bimbatti, Arianna Dri, Alessandra Mosca, Emilio Francesco Giunta, Paola Ermacora, Francesca Vignani, Aichi Msaki, Barbara Bonifacio, Valentina Lombardo, Vincenza Conteduca, Umberto Basso, Giuseppe Fornarini, Giuseppe Luigi Banna
Publikováno v:
The Oncologist. 27:e949-e956
Background Novel androgen receptor signaling inhibitors for prostate cancer (PC) impose the burden of self-administration on older patients overwhelmed by the requirement of many other concomitant medications. Patients and Methods This study evaluate
Autor:
Filippo de Braud, Luigi Mariani, Giancarlo Pruneri, Valentina Guarneri, Enrico Cortesi, Andrea Michelotti, Lucia Del Mastro, Giuseppe Curigliano, Filippo Montemurro, Agnese Losurdo, Daniele Generali, Alessandra Fabi, Rebecca Pedersini, Mariangela Ciccarese, Andrea Rocca, Grazia Arpino, Nicla La Verde, Fabio Puglisi, Lorenzo Gerratana, Salvatore Lo Vullo, Lorenzo Castagnoli, Arta Ajazi, Marika Cinausero, Debora Basile, Anna Moretti, Michela Palleschi, Amelia Vantaggiato, Giovanna Catania, Ottavia Bernocchi, Elisa Agostinetto, Andrea Milani, Dario Trapani, Emanuela Ferraro, Agnese Fabbri, Chiara Molinelli, Claudia De Angelis, Simone Scagnoli, Francesca Ligorio, Carmen G. Rea, Giovanni Randon, Antonio Marra, Gaia Griguolo, Carlo Alberto Giorgi, Luca Moscetti, Luca Lalli, Federico Nichetti, Claudio Vernieri
Supplementary Tables and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2c9b2b078d03a7d71c723d2853b9ca
https://doi.org/10.1158/1078-0432.22479435
https://doi.org/10.1158/1078-0432.22479435
Autor:
Angela, Londero, Marta, Fusi, Marika, Cinausero, Carlo, Tascini, Cristina, Gervasoni, Dario, Cattaneo
Publikováno v:
AIDS. 36:1603-1605
Enzalutamide is an androgen receptor inhibitor used for the treatment of prostate cancer. Although enzalutamide causes a favorable adverse effect profile, it might cause drug-drug interactions with some antiretrovirals. No major differences on the ma